Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Belite Bio, Inc. ADR ( (BLTE) ) has provided an update.
Belite Bio, Inc announced its financial results for the fourth quarter and full year of 2024, alongside a corporate update. The company highlighted the progress of its Phase 3 DRAGON trial for Stargardt disease, which received a positive recommendation from the Data Safety Monitoring Board to continue without modifications. Additionally, the company raised $15 million in a direct offering in February 2025, bolstering its financial position to advance its clinical trials. The company’s financial results showed an increase in research and development expenses, attributed to share-based compensation and trial milestones, while reporting a net loss of $36.1 million for 2024.
More about Belite Bio, Inc. ADR
Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.
YTD Price Performance: 4.15%
Average Trading Volume: 44,650
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.08B
See more data about BLTE stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue